These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21049391)

  • 1. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia.
    Kwaan HC; Rego EM
    Semin Thromb Hemost; 2010 Nov; 36(8):917-24. PubMed ID: 21049391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia.
    Ma G; Liu F; Lv L; Gao Y; Su Y
    Ann Hematol; 2013 May; 92(5):645-52. PubMed ID: 23344645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unique hemostatic dysfunction in acute promyelocytic leukemia.
    Kwaan HC
    Semin Thromb Hemost; 2014 Apr; 40(3):332-6. PubMed ID: 24590422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
    Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
    Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pathogenesis and treatment of the hemostatic disorder in acute promyelocytic leukemia].
    Velasco F; López-Pedrera R; Páramo JA
    Med Clin (Barc); 1996 Jun; 107(2):59-61. PubMed ID: 8753897
    [No Abstract]   [Full Text] [Related]  

  • 6. Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Zhao H; Sun J; Yan L; Jin B; Hou W; Cao F; Li H; Zhou J; Zhang Y
    Ann Hematol; 2021 Jun; 100(6):1473-1483. PubMed ID: 33893844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS).
    Watanabe R; Murata M; Takayama N; Tokuhira M; Kizaki M; Okamoto S; Kawai Y; Watanabe K; Murakami H; Kikuchi M; Nakamura S; Ikeda Y
    Thromb Haemost; 1997 Apr; 77(4):641-5. PubMed ID: 9134635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated hemostasis in acute promyelocytic leukemia.
    Hisada Y
    Int J Hematol; 2024 May; 119(5):526-531. PubMed ID: 38341391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
    Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
    Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of tissue factor-positive microparticles and its clinical significance in the haemostatic disorder].
    Zhou LL; Han Y; Zhu Q; Hu LP; Zhao SX; Zhu MQ; Dai L; Shen WH; Chen L; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):937-40. PubMed ID: 22931659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemostatic changes during the treatment of acute promyelocytic leukemia with all-transretinoic acid].
    Medvedeva NA; Cherepanova VV; Tarasova LN; Kudriavtseva AV; Kostin AI; Kolupaeva OR
    Ter Arkh; 2000; 72(7):27-31. PubMed ID: 10983317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
    Zhang XH; Hu Y; Bao L; Jiang Q; Yang LH; Lu XJ; Hong M; Xia LH; Guo T; Shen GX; Zhu HH; Zhao T; Song SJ
    Chin Med J (Engl); 2009 Sep; 122(17):1969-73. PubMed ID: 19781379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The coagulopathy of acute promyelocytic leukaemia revisited.
    Stein E; McMahon B; Kwaan H; Altman JK; Frankfurt O; Tallman MS
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):153-63. PubMed ID: 19285282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation.
    Koçak U; Gürsel T; Oztürk G; Kantarci S
    Pediatr Hematol Oncol; 2000 Mar; 17(2):177-80. PubMed ID: 10734661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.
    Tallman MS; Abutalib SA; Altman JK
    Semin Thromb Hemost; 2007 Jun; 33(4):330-8. PubMed ID: 17525890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microparticles and procoagulant activity in elderly patients.
    Forest A; Pautas E; Ray P; Bonnet D; Verny M; Amabile N; Boulanger C; Riou B; Tedgui A; Mallat Z; Boddaert J
    J Gerontol A Biol Sci Med Sci; 2010 Apr; 65(4):414-20. PubMed ID: 19942591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microparticle size and its relation to composition, functional activity, and clinical significance.
    Jy W; Horstman LL; Ahn YS
    Semin Thromb Hemost; 2010 Nov; 36(8):876-80. PubMed ID: 21049388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia.
    Kwaan HC; Weiss I; Tallman MS
    Semin Thromb Hemost; 2019 Sep; 45(6):612-621. PubMed ID: 31370070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasma microparticle proteome.
    Little KM; Smalley DM; Harthun NL; Ley K
    Semin Thromb Hemost; 2010 Nov; 36(8):845-56. PubMed ID: 21049385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microparticles and thrombotic disease.
    Davizon P; López JA
    Curr Opin Hematol; 2009 Sep; 16(5):334-41. PubMed ID: 19606028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.